Patients with kidney failure with replacement therapy (ie, dialysis or transplant) appear to be particularly vulnerable to coronavirus disease 2019 (COVID-19) and may have increased mortality.1 Advancing age, comorbid medical conditions, and use of shared dialysis centers in this population likely contribute to the risk. The development of highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been one of the most promising advances of the pandemic; however, patients on kidney replacement therapy (KRT) and/or receiving immunosuppressive therapy were largely excluded from phase 1-3 clinical trials.